Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTHway Adolescent
2025-523928-52-00Phase 3Authorised
- Sponsor
- Ascendis Pharma
- Start
- Mar 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of palopegteriparatide in chronic hypoparathyroidism, sponsored by Ascendis Pharma. Primary endpoints: Week 26 composite biochemical and treatment independence endpoint, Normal albumin-adjusted serum calcium at Week 26 and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
palopegteriparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on 2025-523928-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523928-52-00.